AMY DEMSKE — Lobbyist Profile | Poliscope

AMY DEMSKE

Filings

Clients

Firms

Years active

2024–2024

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
BRISTOL-MYERS SQUIBB COMPANY	2	2024

Lobbying firms

Firm	Filings	Years
BRISTOL-MYERS SQUIBB COMPANY	2	2024

Bills explicitly cited in this lobbyist’s assigned issues (3)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 2630

Extending Temporary Emergency Scheduling of Fentanyl Analogues Act

Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY

Open original LDA filing ↗

Cited source text

Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues

H.R. 8412

Freedom to Haul Act

Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY

Open original LDA filing ↗

Cited source text

Original LDA source filings (2)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY

2024 · fourth_quarter · Q4

Firm income: —Client expense: $790,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act Biosimilars reimbursement issues

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY

2024 · third_quarter · Q3

Source: Senate LDA